Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7028MR)

This product GTTS-WQ7028MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7028MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10149MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ13242MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11962MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ287MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ13051MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5440MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ534MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ15161MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW